维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

4篇 您的检索式：作者名="Matthias Lohn"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Loss of caveolae,vascular dysfunction,and pulmonary defects in caveolin-1 gene-disrupted mice显示文摘	Marek Drab Paul Verkade Marlies Elger Michael Kasper Matthias Lohn Birgit Lauterbach	2001	Science2001，294，：	1
	2	Periadventitial fat releases a vascular relaxing factor显示文摘	Matthias Lohn Dubrovska a Lauterbach B	2002	The FASEB Journal2002，16，：	1
	3	Loss of caveolae,vsacular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice显示文摘	Marek Drab Paul Verkade Marlies Elger Michel Kasper Matthias Lohn Birgit Lauterbach	2001	Science2001，293，：	1
	4	End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899显示文摘AIM: To compare the therapeutic efficacy of SAR407899 with the current standard treatment for hypertension [an angiotensin converting enzyme(ACE)-inhibitor and a calcium channel blocker] and compare the frequency and severity of the hypertension-related end-organ damage. METHODS: Long-term pharmacological characterization of SAR407899 has been performed in two animal models of hypertension, of which one is sensitive to ACE-inhibition and the other is insensitive [deoxycorticosterone acetate(DOCA)]. SAR407899 efficiently lowered high blood pressure and significantly reduced late-stage end organ damage as indicated by improved heart, kidney and endothelial function and reduced heart and kidney fibrosis in both models of chronic hypertension. RESULTS: Long term treatment with SAR407899 has been well tolerated and dose-dependently reduced elevated blood pressure in both models with no signs of tachyphylaxia. Blood pressure lowering effects and protective effects on hypertension related end organ damage of SAR407899 were superior to ramipril and amlodipine in the DOCA rat. Typical end-organ damage was significantly reduced in the SAR407899-treated animals. Chronic administration of SAR407899 significantly reduced albuminuria in both models. The beneficial effect of SAR407899 was associated with a reduction in leukocyte/macrophage tissue infiltration. The overall protective effect of SAR407899 was superior or comparable to that of ACE-inhibition or calciumchannel blockade. Chronic application of SAR407899 protects against hypertension and hypertension-induced end organ damage, regardless of the pathophysiological mechanism of hypertension. CONCLUSION: Rho-kinases-inhibition by the SAR407899 represents a new therapeutic option for the treatment of hypertension and its complications.	Matthias Lohn Oliver Plettenburg Aimo Kannt Markus Kohlmann Armin Hofmeister Dieter Kadereit Peter Monecke Alexander Schiffer Anke Schulte Hartmut Ruetten Yuri Ivashchenko	2015	World Journal of Cardiology2015，7，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费